HT
Halozyme Therapeutics Inc.
HALO· Health Care· BiotechnologyS&P 400
Close · 16/09/2026
108.44
1D
+2.06%52-week range
61.23 – 111.15
Volume
17,09,900.00
Price history
HALO
17/08/2026 to 16/09/2026
O 106.66 H 109.63 L 105.50
1W+0.98%
1M+5.28%
3M+55.72%
6M+66.50%
1Y+42.07%
3Y+189.17%
5Y+157.88%
MAX+143.85%
Fundamentals
as of 16/09/2026- Market cap
- $12.31B
- Shares out
- 113.50M
- P/E (trailing)
- 29.76
- P/E (forward)
- 10.31
- EPS (trailing)
- 3.64
- Beta
- 0.88
- Profit margin
- 24.86%
- P/B
- 85.74
- Return on equity
- 288.13%
SEC financial statements
59 quarterly and 17 annual periods through 30/06/2026.
Details
- Ticker
- HALO
- Index
- SP400
- Sector
- Health Care
- Industry
- Biotechnology
- HQ
- -
Last close 16/09/2026.
Tracked by Congress
3 filers · 1 on watchlist · 1 buy · 5 sells · ?: 1 · D: 5
- 09/03/2026Gilbert CisnerosBuyHalozyme Therapeutics, Inc. - Common Stock$1,001–$15,000
- 24/03/2025Gilbert CisnerosSell+Halozyme Therapeutics, Inc. - Common Stock$1,001–$15,000
- 09/09/2024Josh GottheimerWSell+Halozyme Therapeutics, Inc. - Common Stock$1,001–$15,000
- 12/07/2023Daniel GoldmanSellHalozyme Therapeutics, Inc.$15,001–$50,000
- 06/12/2022Josh GottheimerWSell+Halozyme Therapeutics, Inc.$1,001–$15,000
- 05/08/2022Josh GottheimerWSell+Halozyme Therapeutics, Inc.$1,001–$15,000